ArticleArchives of osteoporosis2025
Association between ramelteon use and risk of fragility fractures: A retrospective cohort study.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparable fracture risk between orexin and melatonin receptor agonists: integrating active-comparator and population-based evidence.Archives of osteoporosis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The effect of melatonin receptor agonists on bone remains unclear. This retrospective cohort study provides the first evidence that the short- to mid-term use of ramelteon is not associated with the risk of fracture. Further research with longer follow-up is needed to clarify the effects of ramelteon on bone health.
backgroundRecent studies have suggested that melatonin may have the potential to treat osteoporosis. However, few studies have examined the effects of melatonin receptor agonists on bone health. This study aimed to evaluate the association between ramelteon use and the risk of fragility fractures.
methodsWe conducted a retrospective cohort study from April 2014 to November 2022 using the DeSC database, a large healthcare claims database in Japan, employing an active comparator and new-user design. Female participants aged ≥ 50 years were included in the study. Exposure was defined as the first dispensation of ramelteon or orexin receptor antagonists. The outcome was a composite of major fragility fractures, including hip, vertebral, wrist, proximal humeral, and ankle fractures. To adjust for potential confounders, we used overlap weighting analysis with propensity scores. Cox regression analyses were performed both before and after applying overlap weighting.
resultsA total of 106,511 individuals were identified, including 23,312 new ramelteon users and 83,199 new orexin receptor antagonist users. The overall fracture incidence was 9,429 per 100,000 person-years in the ramelteon group and 7,330 per 100,000 person-years in the orexin receptor antagonist group. The adjusted hazard ratio for overall fractures associated with ramelteon use was 1.07 (95% confidence interval: 0.99-1.17). The results were consistent across fracture types, age groups, and landmark analyses.
conclusionsIn a real-world setting, short- to mid-term ramelteon use was not associated with an increased risk of fractures. Future studies should consider longer follow-up periods to further investigate the effects of ramelteon on bone health.
Indexed as
Identifiers
40665152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.